Organon's Women's Health segment is dedicated to addressing conditions that uniquely affect women, disproportionately impact them, or have specific implications for their health and well-being. This segment encompasses a broad range of therapeutic areas, including contraception, fertility, and treatments for common gynecological conditions. Research and development efforts focus on innovative solutions that improve women's reproductive health, manage hormonal imbalances, and enhance overall quality of life. The company leverages advanced technologies and methodologies to develop targeted therapies that address unmet needs in women's healthcare. By providing access to essential medicines and promoting awareness, Organon aims to empower women to make informed decisions about their health and lead healthier lives. Future opportunities include expanding the portfolio with novel non-hormonal options and personalized treatments.

The Biosimilars segment at Organon focuses on developing and commercializing biosimilar versions of established biologic medicines. This segment plays a crucial role in increasing access to affordable, high-quality treatments for patients with chronic diseases. Organon's biosimilars portfolio includes products in immunology and oncology, offering cost-effective alternatives to originator biologics. The company invests in rigorous research and development to ensure that its biosimilars meet the same standards of safety and efficacy as the reference products. By leveraging advanced manufacturing technologies and strategic partnerships, Organon aims to expand its biosimilars pipeline and address the growing demand for biosimilar medicines worldwide. Future growth potential lies in developing biosimilars for additional therapeutic areas and expanding market access in emerging economies.

Organon's Established Brands segment comprises a diverse portfolio of well-known and trusted medicines across various therapeutic areas, including cardiovascular, respiratory, dermatology, and pain management. This segment provides a stable revenue stream and allows the company to continue serving patients with essential medicines. While these products may not be new to the market, Organon remains committed to ensuring their availability and affordability. The company focuses on optimizing manufacturing processes, managing supply chains, and maintaining regulatory compliance to support the long-term sustainability of these established brands. Future opportunities include exploring new formulations, indications, and delivery methods to extend the lifecycle of these products and meet evolving patient needs.